The earnings call highlighted significant progress in Gossamer Bio's clinical trials, particularly with the completion of enrollment for the PROSERA study and strategic partnerships. However, there are challenges with delayed timelines and stringent enrollment criteria resulting in a high screening failure rate, alongside financial losses.

Company Guidance

During the Gossamer Bio Q1 2025 earnings call, the company provided a detailed update on their investigational treatment Seralutinib, particularly focusing on the Phase III PROSERA study for pulmonary arterial hypertension (PAH). The call highlighted the completion of patient screenings, with 343 patients enrolled and targeted to complete enrollment by mid-June. The study is powered to detect a 30-meter improvement in the six-minute walk distance at 24 weeks, with anticipated top-line results in February 2026. The baseline characteristics of enrolled patients, including an average six-minute walk distance of 376 meters and a mean NT-proBNP level of 96 ng/L, indicate a sicker population compared to prior studies. Additionally, 74% of patients are classified as functional Class III at baseline. Financially, the company reported $257.9 million in cash and equivalents, with a net loss of $36.6 million for the quarter. The discussion also covered the upcoming Phase III SERANATA study for pulmonary hypertension associated with interstitial lung disease (PH-ILD), which plans to enroll approximately 480 patients globally, aiming to demonstrate improvements in six-minute walk distance and forced vital capacity.

Successful Enrollment in PROSERA Study

Gossamer Bio announced the completion of patient enrollment for the Phase III PROSERA study focused on Seralutinib for PAH, with a total of 343 patients enrolled.

Strategic Global Partnerships

Gossamer Bio highlighted its collaboration with the Chiesi Group, which has enabled Seralutinib to enter a global registrational Phase III study in PH-ILD.

Strong Financial Position

Gossamer ended the quarter with $257.9 million in cash and cash equivalents, providing sufficient capital for operations until the first half of 2027.

Positive Feedback and Interest from Physicians

The open-label extension data from the TORREY study has increased interest and demand for participation in the PROSERA study.

Clear Regulatory Pathway

Discussions with FDA and EMA have confirmed the design and endpoints of the PROSERA study, aligning with regulatory expectations.

Gossamer Bio (GOSS) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

GOSS Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 06, 2025	2025 (Q3)	-0.19 / -	-0.14	―	―	―
Aug 05, 2025	2025 (Q2)	-0.18 / -0.17	0.22	-177.27% (-0.39)	―	―
May 15, 2025	2025 (Q1)	-0.19 / -0.16	-0.19	15.79% (+0.03)	―
Mar 13, 2025	2024 (Q4)	-0.17 / -0.15	-0.21	28.57% (+0.06)	―	―
Nov 07, 2024	2024 (Q3)	-0.15 / -0.14	-0.21	33.33% (+0.07)	―	―
Aug 12, 2024	2024 (Q2)	0.51 / 0.22	-0.45	148.89% (+0.67)	―	―
May 07, 2024	2024 (Q1)	-0.19 / -0.19	-0.52	63.46% (+0.33)	―	―
Mar 05, 2024	2023 (Q4)	-0.21 / -0.21	-0.59	64.41% (+0.38)	―	―
Nov 09, 2023	2023 (Q3)	-0.26 / -0.21	-0.65	67.69% (+0.44)	―	―
Aug 08, 2023	2023 (Q2)	-0.49 / -0.45	-0.74	39.19% (+0.29)	―	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

GOSS Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 05, 2025	$2.16	$1.98	-8.33%
May 15, 2025	$1.05	$1.04	-0.95%
Mar 13, 2025	$1.30	$1.45	+11.54%
Nov 07, 2024	$0.89	$0.88	-1.12%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Gossamer Bio Inc (GOSS) report earnings?

Gossamer Bio Inc (GOSS) is schdueled to report earning on Nov 06, 2025, After Close (Confirmed).

What is Gossamer Bio Inc (GOSS) earnings time?

Gossamer Bio Inc (GOSS) earnings time is at Nov 06, 2025, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is GOSS EPS forecast?

GOSS EPS forecast for the fiscal quarter 2025 (Q3) is -0.19.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing